四環醫藥：2021年度報告.pdf

1、Annual Report 2021 年度報告2021Annual Report年度報告(incorporated in Bermuda with limited liability)（於百慕達註冊成立之有限公司）Stock Code 股份代號：0460Sihuan Pharmaceutical Holdings Group Ltd.四環醫藥控股集團有限公司Sihuan Pharmaceutical Holdings Group Ltd.四環醫藥控股集團有限公司公司簡介CORPORATE PROFILEFounded in 2001 and listed on the Main Board o

2、f The Stock Exchange of Hong Kong Limited in 2010,Sihuan Pharmaceutical Holdings Group Ltd.(“Sihuan Pharmaceutical”or the“Company”,together with its subsidiaries,the“Group”)(Stock Code:00460.HK)is an international medical aesthetic and biopharmaceutical company led and driven by innovation,with a le

3、ading independent production,and research and development(“R&D”)technology platform,a rich global product pipeline and a mature and excellent sales system.Focusing on high-growth therapeutic areas such as medical aesthetics,oncology,metabolism,diabetes,cardiovascular and cerebrovascular,modern Chine

4、se medicine and industrial hemp,it adheres to its overall strategic objective of“Adhering to the full-speed promotion of a two-wheeled strategy of Sihuan medical aesthetics and biopharmaceuticals”to build a leading medical aesthetics and biopharmaceutical enterprise in China.四環醫藥控股集團有限公司（四環醫藥 或本公司，連

5、同其附屬公司為 本集團）（股份代號：00460.HK）創立於二零零一年，二零一零年於香港聯合交易所有限公司主板上市，是一家以創新為引領，堅持創新驅動，擁有獨立領先的自主生產、研究與開發（研發）技術平台，具備豐富的全球化產品管線和成熟卓越銷售體系的國際化醫美及生物製藥企業。四環醫藥聚焦醫美、腫瘤、代謝、糖尿病、心腦血管、現代中藥及工業大麻等高增長治療領域，一直秉承 堅持全速推進四環醫美及生物製藥雙輪驅動戰略 的整體戰略目標來打造中國領先的醫美及生物製藥企業。2 公司資料 Corporate Information5 發展里程 Milestones13 獎項 Awards15 財務摘要 Finan

6、cial Summary16 主席報告 Chairmans Statement22 管理層討論及分析 Management Discussion and Analysis58 董事履歷 Biographical Details of Directors64 企業管治報告 Corporate Governance Report90 董事會報告 Report of Directors119 獨立核數師報告 Independent Auditors Report126 綜合損益及其他全面收益表 Consolidated Statement of Profit or Loss and Other Co